Skip to content

Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men

Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03157778
Acronym
CannaPREG
Enrollment
25
Registered
2017-05-17
Start date
2017-05-30
Completion date
2017-11-02
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

pregnenolone, endocannabinoid, food intake, type-1 cannabinoid receptor

Brief summary

Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese and normal-weight men subjects, to research a dysfunction in the negative feed-back between pregnenolone and CB1 ligand in obese subjects. This dysfunction could participate to the hyperactivity of endocannabinoid system saw in obesity.

Detailed description

Endocannabinoid system is an orexigenic key system, controlling the energy balance. It is composed of receptors (ex: CB1), of endogenous ligands, the endocannabinoids (ex: anandamide and 2- arachidonoylglycerol) and of enzymes implied in the synthesis and the degradation of the endocannabinoids. Researches resulting from our group highlighted anomalies of the plasmatic concentrations of endocannabinoid, in obese subject compared to normal-weight subject. Those being higher in obese subject with a flatness of post prandial reduction of AEA, so maintenance of elevated levels which can facilitate the food catch and create a metabolic vicious circle. In addition, prestigious research resulting from our collaborators highlighted in the animal that exposure to tetrahydrocannabinol (THC, ligand exogenic of CB1) induced the synthesis of pregnenolone (neurosteroid) which, by an autocrine effect on the CB1, inhibited the effects of the THC. In particular one of the principal behavioural effects: the food intake. We want to measure pregnenolone and endocannabinoid concentrations in men blood samples, to observe if this association exists in fasting conditions and over a meal in normal-weight and obese subjects. Obese subjects will be recruited during an hospitalization, while normal subject will be recruited by a poster at Bordeaux university and Haut-Leveque hospital. They will be included at Haut-Leveque hospital during morning at hospital.

Interventions

OTHERObese men

Biological measures before, just before, and after lunch, in obese men

OTHERNormal-weight men

Biological measures before, just before, and after lunch, in normal-weight men.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Obese men versus normal-weight men

Eligibility

Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Obese subjects: * men, * aged between 18 and 65 years, * BMI\>30kg/m2. * Normal-weight subjects: * men, * aged between 18 and 65 years, * BMI\<25kg/m2.

Exclusion criteria

* For all subjects: * cannabis detected by urinary tetrahydrocannabinol presence, * treatment which can interfere with endocannabinoid system (antidepressant, antipsychotics, anxiolytics).

Design outcomes

Primary

MeasureTime frameDescription
Comparison of pregnenolon plasmatic concentration in both groups.Change from 1 hour before lunch to 1 hour after lunch at inclusion dayPregnenolon plasmatic concentration will be measured at several points.

Secondary

MeasureTime frameDescription
Comparison of neurosteroid plasma concentrations and endocannabinoid plasma concentrationsChange from 1 hour before lunch to 1 hour after lunch at inclusion dayNeurosteroid and endocannabinoid plasma concentrations will be measured at several points.
Comparison of endocannabinoid plasma concentration and pregnenolone plasma concentrationChange from 1 hour before lunch to 1 hour after lunch at inclusion dayEndocannabinoid and pregnenolone concentrations will be measured at several points.

Countries

France

Contacts

STUDY_CHAIRLhomme Edouard, Dr

USMR

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026